Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

4F decreases IRF5 expression and activation in hearts of tight skin mice.

Xu H, Krolikowski JG, Jones DW, Ge ZD, Pagel PS, Pritchard KA Jr, Weihrauch D.

PLoS One. 2012;7(12):e52046. doi: 10.1371/journal.pone.0052046. Epub 2012 Dec 14.

2.

Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice.

Weihrauch D, Xu H, Shi Y, Wang J, Brien J, Jones DW, Kaul S, Komorowski RA, Csuka ME, Oldham KT, Pritchard KA.

Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1432-41. Epub 2007 May 11.

3.

An IRF5 Decoy Peptide Reduces Myocardial Inflammation and Fibrosis and Improves Endothelial Cell Function in Tight-Skin Mice.

Weihrauch D, Krolikowski JG, Jones DW, Zaman T, Bamkole O, Struve J, Pillai S, Pagel PS, Lohr NL, Pritchard KA Jr.

PLoS One. 2016 Apr 6;11(4):e0151999. doi: 10.1371/journal.pone.0151999. eCollection 2016.

4.

Abnormal fibrillin-1 expression and chronic oxidative stress mediate endothelial mesenchymal transition in a murine model of systemic sclerosis.

Xu H, Zaidi M, Struve J, Jones DW, Krolikowski JG, Nandedkar S, Lohr NL, Gadicherla A, Pagel PS, Csuka ME, Pritchard KA, Weihrauch D.

Am J Physiol Cell Physiol. 2011 Mar;300(3):C550-6. doi: 10.1152/ajpcell.00123.2010. Epub 2010 Dec 15.

5.

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice.

Weihrauch D, Krolikowski JG, Jones DW, Zaman T, Bamkole O, Struve J, Pagel PS, Lohr NL, Pritchard KA Jr.

J Vis Exp. 2017 Mar 24;(121). doi: 10.3791/55036.

6.

Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.

Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F, Takenaka M, Shimizu K, Asano Y, Hasegawa M, Fujimoto M, Sato S.

Arthritis Rheum. 2010 Aug;62(8):2476-87. doi: 10.1002/art.27498.

7.

Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis.

Saigusa R, Asano Y, Taniguchi T, Yamashita T, Ichimura Y, Takahashi T, Toyama T, Yoshizaki A, Sugawara K, Tsuruta D, Taniguchi T, Sato S.

Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15136-41. doi: 10.1073/pnas.1520997112. Epub 2015 Nov 23.

8.

B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse.

Asano N, Fujimoto M, Yazawa N, Shirasawa S, Hasegawa M, Okochi H, Tamaki K, Tedder TF, Sato S.

Am J Pathol. 2004 Aug;165(2):641-50.

9.

Hepatocyte growth factor ameliorates dermal sclerosis in the tight-skin mouse model of scleroderma.

Iwasaki T, Imado T, Kitano S, Sano H.

Arthritis Res Ther. 2006;8(6):R161.

10.

Targeting of cadherin-11 decreases skin fibrosis in the tight skin-1 mouse model.

Pedroza M, Welschhans RL, Agarwal SK.

PLoS One. 2017 Nov 7;12(11):e0187109. doi: 10.1371/journal.pone.0187109. eCollection 2017.

11.

Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.

Komura K, Fujimoto M, Yanaba K, Matsushita T, Matsushita Y, Horikawa M, Ogawa F, Shimizu K, Hasegawa M, Takehara K, Sato S.

Ann Rheum Dis. 2008 Jun;67(6):867-72. Epub 2007 Sep 6.

PMID:
17823201
12.

CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse.

Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S.

J Clin Invest. 2002 Jun;109(11):1453-62.

13.

Inflammation/oxidation in chronic rejection: apolipoprotein a-i mimetic peptide reduces chronic rejection of transplanted hearts.

Hsieh GR, Schnickel GT, Garcia C, Shefizadeh A, Fishbein MC, Ardehali A.

Transplantation. 2007 Jul 27;84(2):238-43.

PMID:
17667816
14.

Mast cell accumulation and cytokine expression in the tight skin mouse model of scleroderma.

Wang HW, Tedla N, Hunt JE, Wakefield D, McNeil HP.

Exp Dermatol. 2005 Apr;14(4):295-302.

PMID:
15810888
15.

Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice.

Shiota N, Kakizoe E, Shimoura K, Tanaka T, Okunishi H.

Br J Pharmacol. 2005 Jun;145(4):424-31.

16.

The apolipoprotein A-I mimetic peptide, D-4F, alleviates ox-LDL-induced oxidative stress and promotes endothelial repair through the eNOS/HO-1 pathway.

Liu D, Ding Z, Wu M, Xu W, Qian M, Du Q, Zhang L, Cui Y, Zheng J, Chang H, Huang C, Lin D, Wang Y.

J Mol Cell Cardiol. 2017 Apr;105:77-88. doi: 10.1016/j.yjmcc.2017.01.017. Epub 2017 Mar 6.

PMID:
28274624
17.

Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet.

Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, Signorino P, Densmore JC, Kaul S, Oldham KT, Pritchard KA Jr.

Circ Res. 2005 Nov 25;97(11):1190-7. Epub 2005 Oct 13.

18.

Mutant fibrillin 1 from tight skin mice increases extracellular matrix incorporation of microfibril-associated glycoprotein 2 and type I collagen.

Lemaire R, Farina G, Kissin E, Shipley JM, Bona C, Korn JH, Lafyatis R.

Arthritis Rheum. 2004 Mar;50(3):915-26.

19.

Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis.

Stenström M, Nyhlén HC, Törngren M, Liberg D, Sparre B, Tuvesson H, Eriksson H, Leanderson T.

J Dermatol Sci. 2016 Jul;83(1):52-9. doi: 10.1016/j.jdermsci.2016.04.006. Epub 2016 Apr 19.

20.

Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes.

McGaha T, Saito S, Phelps RG, Gordon R, Noben-Trauth N, Paul WE, Bona C.

J Invest Dermatol. 2001 Jan;116(1):136-43.

Supplemental Content

Support Center